antiestrogen

EM-651 (2H-1-Benzopyran-7-ol, 3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (2R)-) is an enantiomer of EM-652, IC50=20.0 nM. EM-652 is an orally active pure antiestrogen and selective estrogen receptor antagonist, IC50=0.44nM.

Trioxifene mesylate is an antiestrogen that suppresses growth hormone secretion.

Anordiol is an antiestrogen with estrogenic activity. It also is known to inhibit fertility.

N-Desmethyltamoxifen hydrochloride is the major tamoxifen metabolite in humans.

Bexirestrant is an orally active ER-α degrader commonly employed in the research of antiestrogen and antineoplastic therapies.

GW7604 is an antiestrogen and it also is the metabolite of GW5638. GW5638 is an antagonist of high-affinity estrogen receptor (ER).

Clometherone is a synthetic pregnane steroid and derivative of progesterone which is used as an antiestrogen and antiandrogen.

Pachyaximine A possesses significant antibacterial activity against Escherichia coli, Staphylococcus aureus, Corynebacterium diphtheriae and Corynebacterium pyrogenes. (-)-Pachyaximine A demonstrates significant activity as antiestrogen binding site (AEBS

OP-1074 is a pure antiestrogen and a selective degrader of ER, shows specific antiestrogenic activity for ERα and ERβ.

Pure antiestrogen that downregulates estrogen receptor expression

Axillaridine A is a new cholinesterase inhibitors, it may act as potential leads in the discovery of clinically useful inhibitors for nervous-system disorders, particularly by reducing memory deficiency in Alzheimer's disease patients by potentiating and

Pipendoxifene, also known as ERA-923, is a new antiestrogen with potential anticancer activity. ERA-923 potently inhibits estrogen binding to ER-alpha (IC50 = 14 nM). In ER-alpha-positive human MCF-7 breast carcinoma cells, ERA-923 inhibits estrogen-stimulated growth (IC50 = 0.2 nM) associated with cytostasis. In vitro, a MCF-7 variant with inherent resistance to tamoxifen (10-fold) or 4-OH tamoxifen (>1000-fold) retains complete sensitivity to ERA-923 . In preclinical models, ERA-923 has an improved efficacy and safety compared with tamoxifen. In the combination with temsirolimus, ERA-923 showed excellent anticancer activity in preclinical models.